COMPLEMENT 3 GLOMERULOPATHY (C3G)

Clinical trials for COMPLEMENT 3 GLOMERULOPATHY (C3G) explained in plain language.

Never miss a new study

Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear

Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

New treatment hope for rare kidney disease patients

Disease control APPROVED_FOR_MARKETING

This program provides early access to pegcetacoplan for people with rare kidney diseases called C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The treatment is for patients aged 12 and older who have active kidney disease and…

Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)

Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Apr 02, 2026 06:42 UTC

COMPLEMENT 3 GLOMERULOPATHY (C3G)

Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear

New treatment hope for rare kidney disease patients